Abstract
This study was conducted to evaluate the efficacy and safety of rituximab and Bortezomib in relapsed or refractory indolent B cell non-Hodgkin’s lymphoma (NHL). Treatments consisted of rituximab 375 mg/m2, i.v. on days 1, 8, 15, and 22 of cycle 1 and on day one of cycles 2–5, bortezomib 1.6 mg/m2, given by intravenous injection (3-s to 5-s bolus) on days 1, 8, 15, and 22 of a maximum of five cycles. The primary end points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and toxicities. From January 2008 to December 2010, 60 successive patients at Tianjin cancer hospital lymphoma department were enrolled in this study. All patients were recurrent or refractory indolent B cell NHL, including follicular lymphoma grades 1–2 (n = 35), small lymphocytic lymphoma/chronic lymphocytic leukemia (LL/CLL; n = 16) and marginal zone lymphoma (n = 9). The median follow-up time was 30 months (range 12–48). The overall response rate was 70.0 %, with a CR/CRu rate of 31.7 %. The 2-year OS and PFS of all patients were 75.0 and 41.0 %, respectively. Grade 3–4 neutropenia and thrombocytopenia occurred in 10 and 3.3 % of patients, respectively. Higher IPI and refractory disease were independently associated with worse survival and PFS. RB chemotherapy in patients with refractory or relapsed indolent B cell NHL was effective with low toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Coiffier B, Thieblemont C, Felman P, Salles G, Berger F. Indolent non-follicular lymphomas: characteristics, treatment and outcome. Semin Hematol. 1999;336:198–208.
Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995;13:140–7.
Kunami N, Katsuya H, Nogami R, et al. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. Anticancer Res. 2014;34(10):5287–94.
Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475–80.
Holkova B, Kmieciak M, Perkins EB, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and “nonhybrid” (Bolus) infusion schedule of alvocidib (Flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014;20(22):5652–62.
Ribrag V, Tilly H, Casasnovas O, et al. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l’Adulte (GELA). Eur J Cancer. 2013;49(4):904–10.
Knapp CM, Whitehead KA, et al. In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma. Expert Opin Drug Deliv. 2014;95(4):1–15.
Ichikawa K, Noguchi M, Koike M, et al. Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. Int J Hematol. 2014;100(4):370–8.
Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561–70.
Furtado M, Johnson R, Kruger A. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol 2014 Aug 22.
Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–12.
Bertrand Coiffi er, Evgenii A Osmanov, Xiaonan Hong, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011;12: 773–84.
Bose P, Batalo MS, Holkova B, et al. Bortezomib for the treatment of non- Hodgkin’s lymphoma. Expert Opin Pharmacother. 2014;15(16):2443–59.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008;168:469–76.
Goda AE, Erikson RL, Sakai T, et al. Preclinical evaluation of bortezomib/dipyridamole novel combination as a potential therapeutic modality for hematologic malignancies. Mol Oncol 2014 Sep 6. pii: S1574-7891(14)00205-1.
Craig M, Hanna WT, Cabanillas F, et al. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2014;166(6):920–8.
Nicholas DB, Raymond T, Kathryn K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475–80.
Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29(25):3389–95.
Jonathan WF, Julie MV, Jennifer LK, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–12.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yun, H., Zhang, H.l. & Wang, Hq. Rituximab and bortezomib (RB): a new effective regimen for refractory or relapsed indolent lymphomas. Med Oncol 32, 353 (2015). https://doi.org/10.1007/s12032-014-0353-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0353-5